Cumberland Pharmaceuticals Files 8-K: Other Events
Ticker: CPIX · Form: 8-K · Filed: Oct 21, 2025 · CIK: 1087294
Sentiment: neutral
Topics: 8-K, other-events
Related Tickers: CPRX
TL;DR
CPRX filed an 8-K for 'Other Events' on Oct 21, 2025. Details TBD.
AI Summary
On October 21, 2025, Cumberland Pharmaceuticals Inc. filed a Form 8-K to report "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This filing indicates that Cumberland Pharmaceuticals Inc. has reported significant events that require disclosure to the public, though the specifics are not yet detailed.
Risk Assessment
Risk Level: medium — The filing is an 8-K for 'Other Events' without immediate specific details, creating uncertainty about the nature and impact of these events.
Key Players & Entities
- CUMBERLAND PHARMACEUTICALS INC. (company) — Registrant
- October 21, 2025 (date) — Filing Date
- Tennessee (location) — State of Incorporation
- Nashville (location) — Principal Executive Offices City
FAQ
What specific 'Other Events' are being reported by Cumberland Pharmaceuticals Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Events' beyond the general categorization.
When was this Form 8-K filed with the SEC?
The Form 8-K was filed on October 21, 2025.
What is the principal business address of Cumberland Pharmaceuticals Inc.?
The principal executive offices are located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203.
What is the SIC code for Cumberland Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Cumberland Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 422 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2025-10-21 09:25:32
Filing Documents
- cpix-20251021.htm (8-K) — 27KB
- cumberlandtaliciaannouncem.htm (EX-99.1) — 29KB
- image_0.jpg (GRAPHIC) — 19KB
- 0001087294-25-000012.txt ( ) — 202KB
- cpix-20251021.xsd (EX-101.SCH) — 2KB
- cpix-20251021_lab.xml (EX-101.LAB) — 21KB
- cpix-20251021_pre.xml (EX-101.PRE) — 12KB
- cpix-20251021_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On October 20, 2025, Cumberland Pharmaceuticals Inc. ("Cumberland") announced strategic arrangements with RedHill Biopharma Ltd. (Nasdaq: RDHL), a specialty biopharmaceutical company, to jointly commercialize Talicia . The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer. A copy of the release is furnished as Exhibit 99.1 . Exhibit No. Description 99.1 Press release dated October 21 , 2025
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cumberland Pharmaceuticals Inc. Dated: October 21, 2025 By: /s/ John Hamm John Hamm Chief Financial Officer